Chemotherapy delayed

The primary reasons why travelers are infected with malaria are failure to take chemotherapy, inappropriate chemotherapy, and delay in seeking medical care. 

Knowing how to prevent and treat adverse events from chemotherapy is an important aspect of patient care. Unmanaged events may result in excess morbidity and cause delays in chemotherapy administration and reduced chemotherapy doses and contribute to treatment failure. 

NK1 agonist-mediated gerbil foot tapping model (ID50 = 0.33 mpk) [34]. Aprepitant (36), which contains seven fluorine atoms, was subsequently approved by the Food and Drug Administration (FDA) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. 

Dexa-BEAM dexamethasone/ carmustine (BCNU)/ etoposide (VP-16)/ cytarabine (Ara-C)/ melphalan Dexamethasone 8 mg PO Q8H days 1 -10 BCNU 60 mg/M2 IV day 2 VP-16 75 mg/M2 IV days 4-7 Ara-C 100 mg/M2 IVQ12H days 4-7 Melphalan 20 mg/M2 IV day 3 REF Pfreundschuh etal. J Clin Oncol 1994 12 580-586 PREMEDICATIONS 1. Kytril 1 mg PO/IV 30 minutes before and 12 hours after chemotherapy on days 2 and 3 2. Compazine 10 mg PO/IV 30 minutes before chemotherapy on days 4-7 OTHER MEDICATIONS 1. Give non-cisplatin delayed emesis prophylaxis Repeat every 28 days Carmustine—maximum total dose is 1440 mg/M2 causes delayed myelosuppression... 

The answer is c. (Hardman, pp 1161-1162.) An important problem in the chemotherapy of TB is bacterial drug resistance For this reason, concurrent administration of two or more drugs should be employed to delay the development of drug resistance. Isoniazid is often combined with ethambutol for this purpose. Streptomycin or rifampin may also be added to the regimen to delay even further the development of drug resistance. 

Dexamethasone has been used successfully in the management of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV), either as a single agent or in combination with selective serotonin reuptake inhibitors (SSRIs). For CINV, dexamethasone is effective in the prevention of both cisplatin-induced acute emesis and when used alone or in combination for the prevention of delayed nausea and vomiting associated with CINV. 

Metoclopramide is used for its antiemetic properties in patients with diabetic gastroparesis and with dexamethasone for prophylaxis of delayed nausea and vomiting associated with chemotherapy administration. 

Nausea and vomiting that occur within 24 hours of chemotherapy administration is defined as acute, whereas when it starts more than 24 hours after chemotherapy administration, it is defined as delayed. The emetogenic potential of the chemotherapeutic agent or regimen (see Table 27-2) is the primary factor to consider when selecting an antiemetic for prophylaxis of CINV. 

Four other dogs were treated with SOAz and cured in the same way. This brings real hope for the clinical treatment of osteosarcoma-bearing patients, especially as there is no chemotherapy available at all for such tumors and that surgery (amputation) is the only technique which might be able to delay death. Incidentally, it may be noted that 16,000 men and women died from osteosarcomas in 1980 in E.E.C. countries. . . ... 

Antiemetic Aprepitant, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. 

Gy in eleven fractions followed by a cycle of cisplatin and etoposide followed by the same schedule of radiation and followed again by chemotherapy. The delayed radiation arm gave the chemotherapy first then started the radiation therapy in wk 18 and again in wk 23. The same chemotherapy and radiation doses were given. The 5-yr survival and local recurrence rate were not statistically different. The 5-yr survival for the early arm was 10.8% vs 12% for the delayed radiation therapy arm. The local recurrence rate for the early radiation arm was 76.6% vs 72.8% for the delayed arm (50). 

Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer a randomized study. J Clin... 

Thrombopoietin is a cytokine that selectively stimulates megakaryocytopoiesis. Thrombopoeitin is not used therapeutically. Theoretical uses include the procurement of platelets for donation and recovery of platelet counts after myelosuppressive chemotherapy. Flowever, a modified recombinant form caused paradoxical reactions, delaying the development of therapeutic thrombopoietin. 

For some indications combination chemotherapy is indicated however then bacteriostatic or bactericidal agents should not be mixed. Synergism between the actions of different drugs is one of the aims of combination therapy. Other indications are delay of development of resistance or the treatment of mixed infections. 

Once the presence of malarial parasites has been confirmed, it is vital to identify the particular plas-modial strain involved, since appropriate use of chemotherapy depends on the particular species responsible for the acute attack. Unfortunately, mixed infections, that is, simultaneous infections with more than one species of plasmodia, are often observed. If more than a single species is involved, treatment appropriate for the elimination of all strains must be instituted to avoid delayed attacks or misinterpretations. 

---